Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress
BION-1301 was well-tolerated, with no serious adverse events (SAEs), treatment discontinuations or events meeting stopping criteria, across a wide range […]